This press release was the EFFDA making a record and creating a narrative of where things stood with LL from their perspective, i.e., favorable to the EFFDA. With the momentum LL has gotten in other countries, the EFFDA knows they are in deep shit so they write about poor trial design and unproven efficacy while conveniently neglecting to mention anything about the incredible safety profile of LL (CD10 patients who got LL did BETTER than the placebo group!).